These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 1646250)

  • 1. Intranasal and intramuscular human calcitonin in female osteoporosis and in Paget's disease of bones: a pilot study.
    Pontiroli AE; Pajetta E; Calderara A; Alberetto M; Pozza G; Manganelli V; Resmini G; Tessari L; Maresca V
    J Endocrinol Invest; 1991 Jan; 14(1):47-51. PubMed ID: 1646250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical and metabolic effects of porcine calcitonin on Paget's disease of bone.
    Shai F; Baker RK; Wallach S
    J Clin Invest; 1971 Sep; 50(9):1927-40. PubMed ID: 4935444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of intranasal human calcitonin in patients with Paget's disease refractory to salmon calcitonin.
    Muff R; Dambacher MA; Perrenoud A; Simon C; Fischer JA
    Am J Med; 1990 Aug; 89(2):181-4. PubMed ID: 2382666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.
    Plosker GL; McTavish D
    Drugs Aging; 1996 May; 8(5):378-400. PubMed ID: 8935399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Calcitonin nasal spray for Paget's disease of the bone].
    Luboshitzky R; Bar-Shalom R
    Harefuah; 1995 Mar; 128(6):358-62, 399. PubMed ID: 7750816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of nasal hCT on bone turnover in Paget's disease of bone--implications for the treatment of other metabolic bone diseases.
    Reginster JY; Jeugmans-Huynen AM; Wouters M; Sarlet N; McIntyre HD; Franchimont P
    Br J Rheumatol; 1992 Jan; 31(1):35-9. PubMed ID: 1730104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Synthetic human calcitonin in Paget's disease of bone and osteoporosis (author's transl)].
    Nuti R; Vattimo A
    Dtsch Med Wochenschr; 1981 Jan; 106(5):149-52. PubMed ID: 6162631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the acute effect of the intranasal and intramuscular administration of salmon calcitonin in Paget's disease.
    González D; Vega E; Ghiringhelli G; Mautalen C
    Calcif Tissue Int; 1987 Dec; 41(6):313-5. PubMed ID: 3124939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analgesic effect of intranasal and intramuscular salmon calcitonin in post-menopausal osteoporosis: a double-blind, double-placebo study.
    Pontiroli AE; Pajetta E; Scaglia L; Rubinacci A; Resmini G; Arrigoni M; Pozza G
    Aging (Milano); 1994 Dec; 6(6):459-63. PubMed ID: 7748920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of calcitonin treatment on the natural course of bone demineralization in Paget's disease.
    Toh SH; Claunch BC; Brown PH
    J Clin Endocrinol Metab; 1983 Feb; 56(2):405-9. PubMed ID: 6822644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcitonin.
    Silverman SL
    Rheum Dis Clin North Am; 2001 Feb; 27(1):187-96. PubMed ID: 11285994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long- and short-term side effects and safety of calcitonin in man: a prospective study.
    Wimalawansa SJ
    Calcif Tissue Int; 1993 Feb; 52(2):90-3. PubMed ID: 8443697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging.
    Clissold SP; Fitton A; Chrisp P
    Drugs Aging; 1991; 1(5):405-23. PubMed ID: 1794028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis].
    Agnusdei D; Gonnelli S; Camporeale A; Batignani T; Nardi P; Ianes A; Gennari C
    Minerva Endocrinol; 1989; 14(3):169-76. PubMed ID: 2695815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.
    Gennari C; Nuti R; Agnusdei D; Camporeale A; Martini G
    Drug Saf; 1994 Sep; 11(3):179-95. PubMed ID: 7811400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the acute effects of subcutaneous and intranasal calcitonin.
    O'Doherty DP; Bickerstaff DR; McCloskey EV; Atkins R; Hamdy NA; Kanis JA
    Clin Sci (Lond); 1990 Feb; 78(2):215-9. PubMed ID: 2155751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increase of axial and appendicular trabecular and cortical bone density in established osteoporosis with intermittent nasal salmon calcitonin therapy.
    Peichl P; Rintelen B; Kumpan W; Bröll H
    Gynecol Endocrinol; 1999 Feb; 13(1):7-14. PubMed ID: 10368793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcitonin.
    Sewell KL
    Rev Rhum Engl Ed; 1997 Jun; 64(6 Suppl):56S-62S. PubMed ID: 9273940
    [No Abstract]   [Full Text] [Related]  

  • 19. Future horizons for calcitonin: a U.S. perspective.
    Carstens JH; Feinblatt JD
    Calcif Tissue Int; 1991; 49 Suppl 2():S2-6. PubMed ID: 1933616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intermittent treatment of Paget's disease of bone with calcitonin: histological study].
    Eisinger J; Laponche AM
    Rev Rhum Mal Osteoartic; 1976; 43(7-9):511-6. PubMed ID: 981933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.